ИНГИБИТОРЫ ПРОДУЦИРОВАНИЯ / СЕКРЕЦИИ β-АМИЛОИДНОГО БЕЛКА

Описывается соединение общей формулы (3): где R15 представляет гетероциклическую группу, выбранную из 3-7-членной насыщенной или 4-7-членной ненасыщенной моноциклической гетероциклической группы, имеющей 1-4 атома, выбранных из атома азота, атома кислорода и атома серы, или 7-14-членной полициклической гетероциклической группы, имеющей 1-4 атома, выбранных из атома азота, атома кислорода и атома серы, которая может иметь заместитель; R16представляет циклоалкильную группу, имеющую 3-7 атомов углерода, моноциклическую ароматическую углеводородную группу, имеющую 6-14 атомов углерода, или гетероциклическую группу, выбранную из 3-7-членной насыщенной или 4-7-членной ненасыщенной моноциклической гетероциклической группы, имеющей 1-4 атома, выбранных из атома азота, атома кислорода и атома серы, которая может иметь заместитель; R17представляет моноциклическую ароматическую углеводородную группу, имеющую 6-14 атомов углерода, или гетероциклическую группу, выбранную из 4-7-членной ненасыщенной ...

Способ получения производных 2-(4-бифенилил)-тетрагидрофурана

SULFONAMIDDERIVATE ALS ASPARTYLPROTEASE-INHIBITOREN

PROCESS FOR PREPARING ADDUCTS OF ALCOHOLS, ETHERS AND ESTERS WITH 1,2-DICHLORODIFLUOROETHYLENE

Verfahren zur Herstellung von Natriumaluminiumhydriden

HETEROCYCLIC COMPOUNDS

2- 4-BIPHENYLYL- TETRAHYDROFURANS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

... 1412663 Substituted tetrahydrofuran compounds and pharmaceutical compositions containing them DR KARL THOMAE GmbH 16 Aug 1973 [17 Aug 1972] 38840/73 Heading C2C The invention comprises compounds of formula wherein R 1 represents hydrogen or a halogen atom. These compounds may be obtained by cyclohydrating a compound of formula wherein R 1 is the same as defined above. Preferred cyclohydrating agents comprise an acid, acid salt, an anhydrous metal salt, a sulphonic acid halide in the presence of a tertiary organic base, or a cation ion-exchanger containing sulphonic acid groups. The intermediate of Formula II is obtained by the reduction of 4,-(4-biphenylyl)-4-oxo-butyric acid esters with complex hydrides; and the intermediate of Formula III is obtained by the reduction of 4-(4-biphenylyl)-but-3-enic acid with complex hydrides. The invention also comprises an anti-philogistical composition which contains as an active ingredient a compound according to the invention in association with a ...

Azabicyclic carbamoyloxy mutilin derivatives for antibacterial use.

Compounds of formula (3), and pharmaceutically acceptable salts and derivatives thereof: in which: R.1 is vinyl or ethyl; and R2 is a group R3, R4CH2~, or R5R6C=CH-; wherein each of R3 and R4 is an azabicyclic ring system or R5 and R^ together with the carbon atom to which they are attached form an azabicyclic ring system, are useful in the prevention and treatment of microbial infections.

Carbamoyloxy derivatives of mutiline and their use as antibacterials.

Derivatives of mutiline of formula (1a)and pharmaceutically acceptable salts and derivatives thereof, in which r1 is ethyl or vinyl, y is a carbamoyloxy group, which the n-atom is unsubstituted, or mono- or di-substituted, are useful in the treatment of bacterial infections.

Novel compounds

Carbamoyloxy derivatives of mutiline and their useas antibacterials.

Nématicides compositions and isecticides containing made up heterocycle.

Carb moylo y der vativ s of utiline and their use as antibacterials

Novel compounds

PROCEDURE FOR the PRODUCTION OF NEW ONE 4 (4-BIPHENYLYL) - BUTANOLEN

PROCEDURE FOR the PRODUCTION OF NEW ONE 2 (4-BIPHENYLYL) - TETRAHYDROFURANES

KOSMETISCHES MITTEL ZUR BEKAMPFUNG DES FETTIGEN UND UNASTHETISCHEN AUSSEHENS DES HAARES UND ZUR VERBESSERUNG DES AUSSEHENS DER HAUT

KOSMETISCHES MITTEL ZUR BEKAMPFUNG DES FETTIGEN UND UNASTHETISCHEN AUSSEHENS DES HAARES UND ZUR VERBESSERUNG DES AUSSEHENS DER HAUT

VERFAHREN ZUR HERSTELLUNG VON NEUEN 4-(4-BIPHENYLYL)-BUTANOLEN

PROCEDURE FOR the PRODUCTION OF NEW ONE 4 (4-BIPHENYLYL) - BUTANOLEN

COSMETIC MEANS TO BEKAMPFUNG THE GREASY AND UNASTHETI APPEARANCE OF THE HAIR AND FOR THE IMPROVEMENT OF THE APPEARANCE OF THE SKIN

SULFONE AMIDE DERIVATIVES AS ASPARTYLPROTEASE INHIBITORS

Procedure for the production of sodium aluminum hydrides

COSMETIC MEANS

TETRAHYDFURAN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS

Carbamoyloxy derivatives of mutiline and their use as antibacterials

Thiosulphonic s-esters as material protective agent

TETRAHYDROFURAN-2-YLMETHYLAMINES

ALPHA,BETA-UNSATURATED SULFONES FOR TREATING PROLIFERATIVE DISORDERS

Sulfones of formula (I) are useful as antiproliferative agents, including, for example, anticancer agents, wherein Q ? 1' is selected from the group consisting of: (a) a phenyl radical according to formula (II), wherein R1, R2, R3, R4 and R5 are in-dependently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, amino, C1-C6 trifluoroalkoxy and trifluoromethyl; (b) an aromatic radical selected from the group consisting of 1-naphthyl, 2-naph-thyl and 9-anthryl; and (c) an aromatic radical according to formula (III), wherein n1 is 1 or 2, Y1 and Y2 are independently selected from the group consisting of hydrogen, halogen, and nitro, and X1 is selected from the group consisting of oxygen, nitrogen, sulfur; and (F2); and Q2 is selected from the group consisting of: (d) a phenyl radical according to formula (II), as defined above; (e) an aromatic radical selected from the group consisting of 1-naphthyl, 2-naphthyl and 9-anthryl; (f) an aromatic radical according to formula (IV) wherein n1 is 1 or 2, Y3 and Y4 are independently selected from the group consisting of hydrogen, halogen, and nitro, and X2, X3 and X4 are independently selected from the group consisting of carbon, oxygen, nitrogen, sulfur and (F2) provided that not all of X2, X3 and X4 may be carbon; and (g) 1-piperazinyl; provided that at least one of Q1 or Q2 is other than a phenyl radical according to formula (II); or a pharmaceutically acceptable salt thereof. Sulfones of formula (V) are also useful as antiproliferative agents, including, for example, anticancer agents, wherein X is sulfur or oxygen; Ya and Yb are independently selected from the group consisting of hydrogen, halogen, and nitro; and R1-R5 are defined as above; or a pharmaceutically acceptable salt thereof.

FUNGICIDAL TRIAZOLE AND IMIDAZOLE DERIVATIVES

Compounds of formula: < IMG > (formula I) and stereoisomers thereof, wherein W is -CH= or =N-; Q is optionally substituted aryl, especially optionally substituted phenyl, optionally substituted aralkyl or alkyl: R1, R2, R3, R4, R5 and R6, which may be the same or different, are H, optionally substituted alkyl, cycloalkyl, aralkyl or optionally substituted phenyl; and R7 and R8 are H, alkyl or optionally substituted phenyl; and acid salts and metal complexes thereof; have fungicidal and plant growth regulating activity.

COMPOSITIONS A BASE DE DERIVES OU HOMOLOGUES DE LA CYSTEAMINE

SULFONATES OF FURAN-2,5-DIMETHANOL AND (TETRAHYDROFURAN-2,5-DIYL)DIMETHANOL AND DERIVATIVES THEREOF

A process for preparing furanic mono- and/or di-sulfonate molecules from the reduction products of HMF, in particular, from either 2,5-bis-hydroxymethyltetrahydrofurans (THF-diols) or furan-2,5-dimethanol (FDM) under relatively mild conditions is described. The process involves reacting THF-diols or FDM with at least a sulfonate species, and a reagent of either 1) a nucleophilic base or 2) combination of a non-nucleophilic base and a nucleophile, as two separate reagents. The furanic sulfonates synthesized according to the process and some of the associated compounds that can be derivatized from the sulfonates are also provided.

CHIRAL IMIDODIPHOSPHATES AND DERIVATIVES THEREOF

The invention relates to chiral imidodiphosphates and derivatives thereof having the general formula I, The compounds are suitable as chiral Brønsted acid catalysts, phase-transfer catalysts, chiral anions for organic salts, metal salts or metal complexes for catalysis.

Verfahren zur Herstellung komplexer organisch substituierter Natriumaluminiumhydride

COMPOSITION POUR LUTTER CONTRE L'ASPECT GRAS ET INESTHETIQUE DE LA CHEVELURE ET POUR AMELIORER L'APPARENCE DE LA PEAU.

Verfahren zur Herstellung von organ. subst. Natriumaluminiumhydriden

Verfahren zur Herstellung von Natriumaluminiumhydriden

Prodn of non-substituted sodium aluminium hydride

Hydrides having the formula Na1+nA1H1+n (in which n is 0 or 2) are prepd. by reacting in a aprotic solvent (esp. hydrocarbons and ethers) under anhydrous conditions and a superatmospheric pressure of H2, Al and Na or NaH in the presence of NaZ, NaAlZ4, AlHZ2, AlH2Z AlZ3NaA1HyZ4-y and HZ (in which y is 1,2 or 3 and Z is an organic residue derived by splitting an active H-atom from (a) ether alcohols obtained by alkylation of one OH group in diols H OR' OH where R' is a divalent hydrocarbon (b) polyether alcohols obtained by alkylation of one OH group in polyglycols obtained by intermolecular dehydration of diols H OR' OH (c) amino-alcohols R2N(CmH2mOH) where R is alkyl and m is an integer from 1 to 15 and (d) tetrahydrofurfuryl alcohols or oxyalkanols.

SULFONIUMDERIVATE.

HERBICIDE EFFECTIVE DERIVATIVES OF OR SUBSTITUTED ARYLMETHYL-1,2,0-ALKYL-IDENE-ALPHA-D-XYLOFURANOSEN 5-DESOXY-3-0-ARYLMETHYL.

KARBAMOILOKSIPROIZVODNYE MUTILIN AND THEIR USE AS ANTIBACTERIAL AGENTS

DERIVATIVES OR HOMOLOGUES OF CYSTEINE

New nitrogenized derivatives substituted by at least a radical naphtyl

PROCESSO PARA A PREPARACAO DE TETRAHIDROFURAN-2-ILMETILAMINAS,COMPOSICOES DE PROTECAO AS PLANTAS,FUNGICIDAS E REGULADORAS DO CRESCIMENTO E PROCESSOS PARA COMBATER FUNGOS E PARA A PREPARACAO DE COMPOSICOES

SORDARIN DERIVATIVES FOR PREVENTING OR TREATING INFECTIOUS DISEASES CAUSED BY PATHOGENIC MICROORGANISMS

This invention relates to a new sordarin derivative or a pharmaceutically acceptable salt thereof, which has antimicrobial activities (especially, antifungal activities), to process for preparation thereof, to a pharmaceutical composition comprising the same, and to a method for prophylactic and/or therapeutic treatment of infectious diseases in a human being or an animal.

Polymeric pyrrolidinium methanesulfonate viscosifiers for aqueous fluids

There are provided polymeric pyrrolidinium methanesulfonate viscosifiers which are useful in chemical waterflooding and in drilling fluids. These compounds may be formed by an unexpected cyclization reaction of quaternary diallyl amino groups on polymeric backbones involving the reaction of such groups with bisulfite salts.

SULFONIUM COMPOUNDS, THEIR PREPARATION AND USE

Compounds of the formula (I), (Ia) or (Ib) wherein A1, and A is for example (II) is 1 or 2; X is C1-C4 alkylene or CO; Y is for example O, O(CO), O(CO)O, R1 is for example hydrogen, d-dsalkyl, C3-C30cycloalkyl, phenyl, naphthyl, anthracyl, phenanthryl, biphenylyl, fluorenyl or C3-C20heteroaryl, all of which optionally are substituted; R2 and R3 for example are C1-C10haloalkylene which is optionally substituted, or R2 and R3 are phenylene, which optionally is substituted; R4 is a group (A) or a group (B); R5 and R6 for example are C1-C20alkyl; or R4 and R5 or R4 and R6 together form a straight-chain C2-C6alkylene, R5 and R6 together form a straight-chain C2-C6alkylene; R7, R8, R9 and R10 ifor example are C1-C20alkyl; M for example is C1-C20alkylene, C2-C20alkenylene, C2-C20alkynylene; R25 and R26 are for example hydrogen, C1-C20alkyl; R27, R28, R29, R30 and R31 are for example hydrogen, C1-C20alkyl, C2-C20alkenyl, C3-C20cycloalkyl, or two radicals R27 and R28, R28 and R29, R29 and R30 and ...

Reversed amidines and methods of using for treating, preventing, or inhibiting leishmaniasis

Methods for treating, preventing or inhibiting leishmaniasis in a subject comprising administering to the subject a therapeutically effective amount of at least one compound having the structural formulawherein Y is a heteroatom; R<1 >and R<2 >are independently H or an alkyl, cycloalkyl, heterocycloalkyl, aryl, amino or heteroaryl group; and X<1>, X<2>, and X<3 >are independently H or an alkyl, alkoxy, halo, amino, alkylamino, dialkylamino, acylamino, alkylthio, sulfonyl, cyano, carboxy, alkoxycarbonyl, or carbamoyl group are disclosed.

PIPERAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS

ИНГИБИТОР АКТИВНОСТИ ХОЛЕСТЕРИН ЭТЕРИФИЦИРОВАННОГО ТРАНСПОРТНОГО БЕЛКА, ПРОФИЛАКТИЧЕСКОЕ ИЛИ ТЕРАПЕВТИЧЕСКОЕ СРЕДСТВО, ПРОИЗВОДНЫЕ БИС-(2-АМИДОФЕНИЛ)ДИСУЛЬФИДА ИЛИ АМИДОТИОФЕНОЛА

FIELD: organic chemistry, pharmacy. SUBSTANCE: invention relates to an inhibitor of activity of cholesterol esterified transport protein comprising as an active component the compound presented by the formula (I) where R means direct or branched alkyl group; lower halogenalkyl group; substituted or unsubstituted cycloalkyl group; substituted or unsubstituted cycloalkylalkyl group; substituted or unsubstituted aryl group, or substituted or unsubstituted heterocyclic group; X 1 , X 2 , X 3 , X 4 can be similar or different and each means hydrogen atom, halogen atom, lower alkyl group, lower halogenalkyl group; lower alkoxy-group; cyano-group; nitro-group; Y means CO- and Z means hydrogen atom or mercapto-protecting group, or its pharmaceutically acceptable salt or hydrate, or solvate. Compounds presented by the formula (I) can increase the level of high density lipoproteins (HDL) and in the same time decrease the level of low density lipoproteins (LDL) by selective inhibition of activity of cholesterol esterified transport protein and therefore as suggested they can be used as prophylactic or therapeutic agents of new type for treatment of atherosclerosis or hyperlipidemia. EFFECT: new compounds indicated above, valuable medicinal properties. 24 cl, 48 tbl (19) 13) ВО” 2 188 631” С2 ОМК’ А бл К 31/165, 31/44, С 07 С 323/40, 323/63, 323/65, С 07 0 с эз8з с ПЧ сэ РОССИЙСКОЕ АГЕНТСТВО ПО ПАТЕНТАМ И ТОВАРНЫМ ЗНАКАМ 211/62, 213/81, А 61 Р 3/06 12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ РОССИЙСКОЙ ФЕДЕРАЦИИ (21), (22) Заявка: 99119494/04, 10.02.1998 (24) Дата начала действия патента: 10.02.1998 (30) Приоритет: 12.02.1997 /Р 9/44836 05.06.1997 УР 9/165085 23.01.1998 УР 10/26688 (43) Дата публикации заявки: 21.07.2001 (46) Дата публикации: 10.09.2002 (56) Ссылки: ЗИ 499261, А, 06.07.1976. ММО 95/01326, АЛ, 12.01.1995. \МО 9203412, АЛ, 05.03.1992. КУ 94046149, СЛ, 27.11.1996. ММО 9203408, АЛ, 05.03.1992. (85) Дата перевода заявки РСТ на национальную фазу: 13.09.1999 (86) Заявка РСТ: ...

ПИПЕРАЗИНОВЫЕ ПРОИЗВОДНЫЕ, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯЖЕЛУДОЧНО-КИШЕЧНЫХ РАССТРОЙСТВ

ÐÎÑÑÈÉÑÊÀß ÔÅÄÅÐÀÖÈß (19) RU (11) 2007 107 349 (13) A (51) ÌÏÊ C07D 409/04 (2006.01) ÔÅÄÅÐÀËÜÍÀß ÑËÓÆÁÀ ÏÎ ÈÍÒÅËËÅÊÒÓÀËÜÍÎÉ ÑÎÁÑÒÂÅÍÍÎÑÒÈ, ÏÀÒÅÍÒÀÌ È ÒÎÂÀÐÍÛÌ ÇÍÀÊÀÌ (12) ÇÀßÂÊÀ ÍÀ ÈÇÎÁÐÅÒÅÍÈÅ (21), (22) Çà âêà: 2007107349/04, 26.07.2005 (71) Çà âèòåëü(è): ÃËÝÊÑÎ ÃÐÓÏ ËÈÌÈÒÅÄ (GB) (30) Êîíâåíöèîííûé ïðèîðèòåò: 28.07.2004 GB 0416844.9 08.07.2005 GB 0514029.8 (85) Äàòà ïåðåâîäà çà âêè PCT íà íàöèîíàëüíóþ ôàçó: 28.02.2007 (87) Ïóáëèêàöè PCT: WO 2006/010629 (02.02.2006) R U (54) ÏÈÏÅÐÀÇÈÍÎÂÛÅ ÏÐÎÈÇÂÎÄÍÛÅ, ÏÐÈÌÅÍÅÍÈÅ ÄËß ËÅ×ÅÍÈß ÆÅËÓÄÎ×ÍÎÊÈØÅ×ÍÛÕ ÐÀÑÑÒÐÎÉÑÒ (57) Ôîðìóëà èçîáðåòåíè 1. Ñîåäèíåíèå ôîðìóëû (I): A 2 0 0 7 1 0 7 3 4 9 A Àäðåñ äë ïåðåïèñêè: 129010, Ìîñêâà, óë. Á.Ñïàññêà , 25, ñòð.3, ÎÎÎ "Þðèäè÷åñêà ôèðìà Ãîðîäèññêèé è Ïàðòíåðû", ïàò.ïîâ. À.Â.Ìèöó ãäå R a ïðåäñòàâë åò ñîáîé àðèë èëè ãåòåðîàðèë; Y ïðåäñòàâë åò ñîáîé ïðîñòóþ ñâ çü, CH2, CH2CH2 èëè CH=CH; R b ïðåäñòàâë åò ñîáîé âîäîðîä èëè C1-6àëêèë; R c ïðåäñòàâë åò ñîáîé âîäîðîä èëè ìåòèë; R d ïðåäñòàâë åò ñîáîé C1-6àëêèë; R e ïðåäñòàâë åò ñîáîé âîäîðîä, C1-6àëêèë, C3-6öèêëîàëêèë, COC1-6àëêèë, C1-6àëêîêñè, ãàëîãåí, ãèäðîêñèë, òðèôòîðìåòèë, òðèôòîðìåòîêñè èëè öèàíî; è R f ïðåäñòàâë åò ñîáîé âîäîðîä, C1-6àëêèë, C3-6öèêëîàëêèë, COC1-6àëêèë, C1-6àëêîêñè, C1Ñòðàíèöà: 1 RU 2 0 0 7 1 0 7 3 4 9 (86) Çà âêà PCT: EP 2005/008263 (26.07.2005) R U (43) Äàòà ïóáëèêàöèè çà âêè: 10.09.2008 Áþë. ¹ 25 (72) Àâòîð(û): ÄÆÀÈÁÀ Àëåññàíäðà (GB), ÊÈÍà Íàéäæåë Ïîë (GB), ÒÝÊË Ýíäðþ Êåííåò (GB), ÂÈÇÅÐÈÍÃÒÎÍ Äæåéñîí (GB), ÄÈÍ Äýâèä Êåííåò (GB) àëêîêñèC1-6àëêèë, ãàëîãåí, ãèäðîêñèë, òðèôòîðìåòèë èëè öèàíî, èëè åãî ôàðìàöåâòè÷åñêè ïðèåìëåìà ñîëü. 2. Ñîåäèíåíèå ôîðìóëû (IA): 2 0 0 7 1 0 7 3 4 9 R U A Ñòðàíèöà: 2 2 0 0 7 1 0 7 3 4 9 ãäå R a, R b, R c, R d, R e, R f è Y âë þòñ òåìè, êàê îïðåäåëåíî â ï.1, èëè åãî ôàðìàöåâòè÷åñêè ïðèåìëåìà ñîëü. 3. Ñîåäèíåíèå ôîðìóë (I) èëè (IA), ãäå R a íåîá çàòåëüíî çàìåùåí îò îäíîãî äî òðåõ çàìåñòèòåë ìè, âûáðàííûìè èç C1-6àëêèëà, ãàëîãåíà, äèìåòèëàìèíî, òðèôòîðìåòèëà, íåîá çàòåëüíî çàìåùåííîãî àðèëà èëè íåîá ...

INHIBITOREN DER CETP-AKTIVITÄT

Isocyanocarboxylic acid (esters) - from acrylonitrile etc

Parent patent describes prepn. of carboxylic acid (esters) by reaction of an alpha-isocyanoalkane carboxylic acid ester of formula: (where R' = H, 1 - 15C alkyl or an aromatic or hetero-aromatic gp, R2 = all gps. suitable for esterification with a 1,2-unsaturated carboxylic acid of formula: (where R3, R4 and R5 = H, (cyclo)alkyl or (hetero)aryl and one of the gps. can be -COOR2. R6 has the same definition as R2 in the presence of a base.) In place of component II a cpd. of formula: is used (where Z = an electron withdrawing substituent).

HERBICIDALLY ACTIVE 5-DEOXY-3-O-ARYLMETHYL DERIVATIVES

4-/4-BIPHENYLZL/-1-BUTANOLS

... 1368375 Biphenyl butanols DR KARL THOMAE GmbH 13 Oct 1972 [15 Oct 1971] 47441/72 Heading C2C The invention comprises compounds having the general formula wherein R 1 is a halogen atom or an amino group; R 2 is a hydrogen or halogen atom; and R 3 is a hydrogen atom or a hydroxy group; and, in the case where R 1 is an amino group, acid addition salts thereof. They may be prepared by (A) in the case where R 3 is a hydrogen atom, by reducing any of the following compounds or by catalytically hydrogenating either of the compounds or (B) in the case where R 3 is a hydroxy group, by reducing any of the following compounds wherein B is a hydroxy, alkoxy, aralkoxy, aryloxy, or acyloxy group or a halogen atom; A is a hydroxymethylene or keto group; Y and Z are each hydrogen atoms or together represent a double bond; and B1 is a hydroxy, alkoxy, aralkoxy or aryloxy group, or (provided A is a keto group) an acyloxy group or (provided A is a keto group and Y and Z together represent a double ...

SULPHONIUM COMPOUNDS

Fluorinated ethers

PCT No. PCT/GB84/00013 Sec. 371 Date Sep. 11, 1984 Sec. 102(e) Date Sep. 11, 1984 PCT Filed Jan. 20, 1984 PCT Pub. No. WO84/02909 PCT Pub. Date Aug. 2, 1984.Fluorinated ether, process for their preparation, and use of the fluorinated ethers as inert fluids.

ALPHA, BETA-INSATIATED SULFONES FOR THE TREATMENT OF CELL RAMPANT GROWTH DISTURBANCES

PROCEDURE FOR the PRODUCTION OF NEW ONE 4 (4-BIPHENYLYL) - BUTANDIOLEN

Chiral imidodiphosphates and derivatives thereof

The invention relates to chiral imidodiphosphates and derivatives thereof having the general formula I, The compounds are suitable as chiral Brønsted acid catalysts, phase-transfer catalysts, chiral anions for organic salts, metal salts or metal complexes for catalysis.

5-DEOXY-3-0-ARYLMETHYL OR SUBSTITUTED ARYLMETHYL-1,2- 0-ALKYLIDENE-A-D-XYLOFURANOSE HERBICIDE DERIVATIVES

... 5-Deoxy-3-O-arylmethyl or substituted arylmethyl-1,2-O-alkylidene-a-D-xylofuranose and 5-C-alkyl and alkenyl derivatives thereof. The compounds are useful as herbicides and plant growth regulators.

COMPOSITIONS A BASE DE DERIVES OU HOMOLOGUES DE LA CYSTEAMINE

PRECIS DE LA DIVULGATION: Une nouvelle composition pour lutter contre l'aspect gras et inesthétique de la chevelure et pour améliorer l'appa-rence de la peau, caractérisée par le fait qu'elle contient, en combinaison dans un véhicule approprié, au moins un composé actif correspondant à la formule suivante : . PRECISION OF DISCLOSURE: A new composition to fight against the appearance oily and unsightly of the hair and to improve the appearance rence of the skin, characterized in that it contains, in combination in an appropriate vehicle, at least one active compound corresponding to the following formula: .

SULPHONAMIDE DERIVATIVES AS ASPARTYL PROTEASE INHIBITORS

This invention relates to a novel class of sulfonamides that are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of aspartyl protease inhibitors characterized by specific structural and physiochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting aspartyl protease activity and methods for treating viral infections using the compounds and compositions of this invention.

AZABICYCLIC CARBAMOYLOXY MUTILIN DERIVATIVES FOR ANTIBACTERIAL USE

Compounds of formula (3), and pharmaceutically acceptable salts and derivatives thereof, in which R1 is vinyl or ethyl; and R2 is a group R3, R4CH2-, or R5R6C=CH-; wherein each of R3 and R4 is an azabicyclic ring system or R5 and R6 together with the carbon atom to which they are attached form an azabicyclic ring system, are useful in the prevention and treatment of microbial infections.

COMPOSITIONS BASED ON DERIVATIVES OR HOMOLOGUES OF CYSTEAMINE FOR COUNTERACTING THE GREASY APPEARANCE OF THE HEAD OF HAIR AND OF THE SKIN

4-/4-BIPHENYLZL/-1-BUTANOLS

Process for the preparation of aluminium-sodium hydrides

Method of preparation of new vinyl sulphides

HETEROCYCLIC ALKYLTHIOCYANATE AND ISOTHIOCYANATE PLANT GROWTH REGULATORS

PROCESS FOR PREPARING SUBSTITUTED HEXAHYDRO BENZO [E INDENE AND OCTAHYDRO PHENANTHRENE

Title compds. (I) [m=0,1,2; t=1,2; M=CH, N; R1=H, benzyl, benzoyl, C1-5 alkanoyl, etc.; Q=CO2R4, COR5, 5-tetrazollyl, etc.; R4=H, C1-4 alkyl, benzyl; R5=H, C1-4 alkyl, Ph, benzyl , useful as an analgesic, were prepd.. Thus, a mixt. contg. 28.6g 3, 5-dimethoxy-β-nitrostyrene, 20 g butadiene, 40ml toluene, and small amt. of hydroquinone was cooled to -78↿C under nitrogen followed by boiling at 100↿C for 48hr, cooled again, concentrated, and crystallized by MetOH to give 29.8g 4-(3,5-dimethoxyphenyl)-5nitrocyclohexene. Copyright 1997 KIPO ...

Pharmaceutical composition for treating or preventing diseases attributed to CETP activity

The present invention provides a CETP activity inhibitor comprising as an active ingredient a compound represented by the formula (I), wherein R represents a straight chain or branched alkyl group; a straight chain or branched alkenyl group; a lower haloalkyl group; a substituted or unsubstituted cycloalkyl group; a substituted or unsubstituted cycloalkenyl group; a substituted or unsubstituted cycloalkylalkyl group; a substituted or unsubstituted aryl group, or a substituted or unsubstituted heterocyclic group, X1, X2, X3, and X4 may be the same or different and each represents a hydrogen atom, a halogen atom, a lower alkyl group, a lower haloalkyl group; a lower alkoxy group; a cyano group; a nitro group; an acyl group; or an aryl group, Y represents -CO- or -SO2-, and Z represents a hydrogen atom or a mercapto-protecting group, or a prodrug compound, a pharmaceutically acceptable salt, or hydrate or solvate thereof. The compounds represented by the formula (I) can increase HDL and at ...

Process for preparing optically active haloalcohols

A process for producing the optically pure (+)- or (-) isomer of a phenyl- or substituted- phenylalkanolamine compounds having pharmacologic activity without the need for resolution processes and novel intermediates useful in the process including optically pure haloalcohols are provided.

Beta-amyloid protein production. secretion inhibitor

Provided are novel compounds having an inhibitory activity against production or secretion of β-amyloid protein. They embrace compounds represented by the following formula (1): and capable of being replaced with a variety of substituents; and salts thereof, and solvates of any one of them.

Tetrahydrofuran compounds and analogs thereof

There are disclosed tetrahydrofuran compounds and analogs thereof of the formula: and pharmaceutically acceptable acid addition salts thereof, wherein X is oxygen or sulfur, R1 and R2 are each hydrogen, halogen, lower alkyl or lower alkoxy, and Am is a group of the formula: +TR wherein Z is oxygen or sulfur, R3 is hydrogen or halogen, R4 is hydrogen, lower alkyl or phenyl which may be substituted by 1 to 3 substituents at any position(s) on the phenyl nucleus, each substituent being independently selected from halogen, lower alkyl and lower alkoxy, and R5 is hydrogen or lower alkyl. Such compounds are useful as neuroleptics.

Alpha, beta-unsaturated sulfones for treating proliferative disorders

Sulfones of formula I are useful as antiproliferative agents, including, for example, anticancer agents: wherein: Q1 is selected from the group consisting of (a) a phenyl radical according to formula II wherein R1, R2, R3, R4 and R5 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, amino, C1-C6 trifluoroalkoxy and trifluoromethyl; (b) an aromatic radical selected from the group consisting of 1-naphthyl, 2-naphthyl and 9-anthryl; and (c) an aromatic radical according to formula III wherein n1 is 1 or 2, Y1 and Y2 are independently selected from the group consisting of hydrogen, halogen, and nitro, and X1 is selected from the group consisting of oxygen, nitrogen, sulfur and Q2 is selected from the group consisting of (d) a phenyl radical according to formula II, as defined above; (e) an aromatic radical selected from the group consisting of 1-naphthyl, 2-naphthyl and 9-anthryl; (f) an aromatic radical according ...

CETP ACTIVITY INHIBITORS

ИММУНОДЕПРЕССАНТНЫЕ СОЕДИНЕНИЯ И КОМПОЗИЦИИ

FIELD: medicine, pharmaceutics. SUBSTANCE: present invention refers to compounds of formula Ia and their pharmaceutically acceptable salts, hydrates, solvates, esters and amides. In formula Ia , A is specified from -C(O)OR 5 where R 5 represents hydrogen; W represents C 1-3 alkylene; Y is specified from phenyl and 5-6-member heteroaryl containing one heteroatom specified from N, S, O; where any phenyl or heteroaryl Y can be optionally substituted with 1 to 3 radicals specified from halogen, C 1-6 alkyl, C 1-6 alkoxygroup, halogen-substituted C 1-6 alkyl and halogen-substituted C 1-6 alkoxygroup; Z is specified from: where left and right asterisks Z specify an attachment point between -C(R 3 )(R 4 )- and A of formula la; R 6 is specified from hydrogen and C 1-6 alkyl; or R 6 can be attached to carbon atom in Y to form a 5-7-member ring; R 1 is specified from phenyl and 5-member heteroaryl containing one heteroatom specified from S, O; where any phenyl or heteroaryl R 1 is substituted with a radical specified from phenylC 0-4 alkyl, heteroarylC 0-4 alkyl where heteroaryl represents 5-6-member heteroary containing one heteroatom specified from N, S, O, C 3-8 cycloalkylC 0-4 alkyl, C 3-8 heterocycloalkylC 0-4 alkyl which contains nitrogen atom as heteroatom, or C 1-6 alkyl; where any phenyl, heteroaryl, cycloalkyl or heterocycloalkyl group R 1 can be optionally substituted with 1 to 3 radicals specified from halogen, C 1-6 alkyl, C 1-6 alkoxygroup, halogen-substituted C 1-6 alkyl group and halogen-substituted C 1-6 alkoxygroup; R 2 represents C 1-6 alkyl group; R 3 and R 4 represent hydrogen. EFFECT: preparation of the pharmaceutical composition exhibiting EDG/S1P receptor modulating properties, containing therapeutically effective amount of the compound under the invention, development of a method of treating the disease mediated by EDG/S1P receptor activity, application of the compounds for preparing a drug for prevention or treatment of the disease mediated by EDG/ ...

ИММУНОДЕПРЕССАНТНЫЕ СОЕДИНЕНИЯ И КОМПОЗИЦИИ

... 1. Соединение, выбранное из формулы Ia и Ib в которых А выбирают из -C(O)OR5, -OP(O)(OR5)2, -P(O)(OR5)2, -S(O)2OR5, -P(O)(R5)OR5 и 1H-тетразол-5-ила; где каждый R5 независимо выбирают из водорода и C1-6алкила; W выбирают из связи, C1-3алкилена, С2-3алкенилена; Y выбирают из С6-10арила и С2-9гетероарила; где любой арил или гетероарил Y может быть необязательно замещен от 1 до 3 радикалами, выбранными из галогруппы, гидроксигруппы, нитрогруппы, C1-6алкила, С1-6алкоксигруппы, галозамещенного С1-6алкила и галозамещенной C1-6алкоксигруппы; Z выбирают из где левая и правая звездочки Z указывают точку присоединения между -С(R3)(R4)- и А формулы Ia или Ib; R6 выбирают из водорода и C1-6алкила; и J1 и J2 независимо обозначают метилен или гетероатом, выбранный из S, О и NR5; где R5 выбирают из водорода и С1-6алкила; и любой алкилен Z может быть далее замещен от 1 до 3 радикалами, выбранными из галогруппы, гидроксигруппы, С1-6алкила; или R6 может быть присоединен к атому углерода в Y с образованием ...

ИНГИБИТОРЫ ПРОДУЦИРОВАНИЯ / СЕКРЕЦИИ B-АМИЛОИДНОГО БЕЛКА

Измененная формула изобретения, предложенная заявителем для рассмотрения 1. Соединение, представленное следующей формулой (3): (где R15 представляет гетероциклическую группу, которая может иметь заместитель, R16 представляет циклическую углеводородную группу, которая может иметь заместитель, или гетероциклическую группу, которая может иметь заместитель, R17 представляет циклическую углеводородную группу, которая может иметь заместитель, или гетероциклическую группу, которая может иметь заместитель, R18 представляет атом водорода или С1-6алкильную группу, а Х представляет –S-, -SO- или –SO2-); или N-оксид или S-оксид данного соединения; их соль; или сольват описанного выше соединения. 2. Соединение по п.1, где Х представляет –SO- или –SO2-; или N-оксид или S-оксид данного соединения; их соль; или сольват описанного выше соединения. 3. Соединение по п.1, где Х представляет –SO2-; или N-оксид или S-оксид данного соединения; их соль; или сольват описанного выше соединения. 4. Соединение по ...

Способ получения 4-(4-бифенилил)-бутанолов

NEUE SULFONIUMVERBINDUNGEN, VERFAHREN ZU DEREN HERSTELLUNG UND DIESE ENTHALTENDE ARZNEIMITTEL

Neue anionische Tenside und Wasch- und Reinigungsmittel, welche diese enthalten

Tenside der allgemeinen Formel (I),in der Rund Runabhängig voneinander für H und SOXstehen mit der Maßgabe, dass mindestens eines von Rund Rnicht H ist, n und m unabhängig voneinander für Zahlen von 0 bis 21 stehen mit der Maßgabe, dass 4 < n + m < 26, und Xfür ein ladungsausgleichendes Kation steht, lassen sich gut in Wasch- oder Reinigungsmittel einarbeiten, besitzen herausragende anwendungstechnische Eigenschaften und können auf Basis nachwachsender Rohstoffe hergestellt werden.

Substituted dialkyl-sulphoxides and sulphones

The invention comprises compounds of formula R-CH2-S(O)n-CH3 wherein R is a 5- or 6-membered heterocyclic ring containing one oxygen or sulphur atom as its hetero-atom and n is 1 or 2, and their preparation by oxidation of a corresponding compound of formula RCH2SCH3. The compounds of the invention have antiinflammatory and analgesic activity and may be used in pharmaceutical compositions in combination with a carrier, for example in forms suitable for oral, parenteral or topical administration.

Heterocyclic thiocyanates and isothiocyanates, their inter mediates and methods of producing such compounds

The invention comprises thiocyanates of the tetrahydrofuran and tetrahydropyran series having the respective formul : and the corresponding isothiocyanates. The 2- and 3-bromomethyl derivatives of tetrahydropyran are also novel compounds. The thiocyanates and isothiocyanates are produced by heating a corresponding halomethyl compound, preferably the bromide, with an inorganic thiocyanate such as ammonium thiocyanate in a solvent such as dioxane, a mixture of ethyl alcohol and water or a mixture of ethyl alcohol and dioxane. The 2- and 3-bromomethyl derivatives of tetrahydropyran may be prepared by heating phosphorus tribromide with the corresponding alcohol. The phosphorus tribromide may be prepared in situ by adding bromine to a solution of phosphorus in the alcohol. In examples, (1) tetrahydrofurfuryl bromide is added to a solution of ammonium thiocyanate in alcohol and the mixture is refluxed for 20 hours, then poured into water, extracted with ether, dried, distilled ...

PROCEDURE FOR the PRODUCTION OF NEW ONE 4 (4-BIPHENYLYL) - BUTANOLEN

Procedure for the production of new 4 (4-Biphenylyl) - butanolen

SUBSTITUTED HEXAHYDROPYRROLO (1,2-A) CHINOLINE, HEXAHYDRO-1H-PYRIDO (1,2-A) - CHINOLINE, HEXAHYDROBENZO (E) INDENE AND OCTAHYDROPHENANTHRENE AS MEANS WITH EFFECT ON the CENTRAL NERVOUS SYSTEM.

Fluorinated monomer of cyclic acetal structure, polymer, resist protective coating composition, resist composition, and patterning process

A fluorinated monomer of cyclic acetal structure has formula (1) wherein R is a C 1 -C 20 alkyl group which may be substituted with halogen or separated by oxygen or carbonyl, and Z is a divalent organic group which forms a ring with alkylenoxy and contains a polymerizable unsaturated group. A polymer derived from the fluorinated monomer may be endowed with appropriate water repellency, water sliding property, lipophilicity, acid lability and hydrolyzability and is useful in formulating a protective coating composition and a resist composition.

SULFONIUM COMPOUNDS, THEIR PREPARATION AND USE

Compounds of the formula (I), (Ia) or (Ib) wherein A, and A is for example (II) is 1 or 2; X is C-Calkylene or CO; Y is for example O, O(CO), O(CO)O, Ris for example hydrogen, d-dsalkyl, C-Ccycloalkyl, phenyl, naphthyl, anthracyl, phenanthryl, biphenylyl, fluorenyl or C-Cheteroaryl, all of which optionally are substituted; Rand Rfor example are C-Chaloalkylene which is optionally substituted, or Rand Rare phenylene, which optionally is substituted; Ris a group (A) or a group (B); Rand Rfor example are C-Calkyl; or Rand Ror Rand Rtogether form a straight-chain C-Calkylene, Rand Rtogether form a straight-chain C-Calkylene; R, R, Rand Rifor example are C-Calkyl; M for example is C-Calkylene, C-Calkenylene, C-Calkynylene; Rand Rare for example hydrogen, C-Calkyl; R, R, R, Rand Rare for example hydrogen, C-Calkyl, C-Calkenyl, C-Ccycloalkyl, or two radicals Rand R, Rand R, Rand Rand/or Rand Rtogether form a straight-chain C-Calkylene, or Rand Rtogether form 1,2-phenylene, Rand Rfor example are hydrogen, C-Calkyl; R, Rand Rfor example are hydrogen, C-Calkyl; are suitable as thermo-acid generators. 3: A heat-curable composition comprising(a) at least one compound which is capable of undergoing cationic polymerization; and{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, '(b) at least one compound of formula I, Ia or Ib according to .'}4: The heat-curable composition according to claim 3 , wherein the compound which is capable of undergoing cationic polymerization has at least one group selected from the group consisting of an epoxy group claim 3 , oxetane group and vinyl ether group.5: The heat-curable composition according to claim 3 , where the compound which is capable of undergoing cationic polymerization is an epoxy resin.6: The heat-curable composition according to claim 3 , further comprising at least one component selected from the group consisting of solvent claim 3 , reactive diluents claim 3 , photoinitiators claim 3 , photoacid generators claim 3 , pigments ...

POLYMERIZABLE COMPOSITION COMPRISING AN OXIME SULFONATE AS THERMAL CURING AGENT

The present invention relates to a polymerizable composition comprising at least one ethylenically unsaturated, polymerizable compound and at least one oxime sulfonate compound of the formula I 144-. (canceled)47. The compound of formula I according to claim 45 , where X is S or NRand{'sup': 14', '6', '14a', '8', '9', '10', '11', '4', '5', '6', '7', '8', '9', '10', '11, 'sub': 1', '12', '3', '8', '1', '8', '1', '4', '2, 'claim-text': [{'sub': 2', '12', '3', '8', '1', '8', '1', '4', '2, 'sup': 6', '14a', '8', '9', '10', '11', '4', '5', '6', '7', '8', '9', '10', '11, 'C-C-alkenyl, which may be interrupted by one or more O, S, NRor CO and/or may be substituted by one or more identical or different radicals Rselected from CN, COR, COOR, CONRR, phenyl and C-C-cycloalkyl which may interrupted by one or two CO groups and where the two last-mentioned radicals may be substituted by one or more identical or different radicals selected from C-C-alkyl, C-C-haloalkyl, F, Cl, Br, I, CN, NO, SR, OR, NRR, COR, COORand CONRR;'}, {'sub': 3', '12', '1', '8, 'sup': 14b', '8', '9', '10', '11, 'C-C-cycloalkyl, which may be interrupted by one or more CO and/or may be substituted by one or more identical or different radicals Rselected from C-C-alkyl, CN, COR, COOR, CONRR;'}, {'sup': 14c', '4', '5', '6', '7', '8', '9', '10', '11, 'sub': 1', '6', '1', '4', '2, 'phenyl, which may be substituted by one or more identical or different radicals Rselected from C-C-alkyl, C-C-haloalkyl, F, Cl, Br, I, CN, NO, SR, OR, NRR, COR, COOR, CONRRand phenyl,'}, 'or', {'sup': '14', 'two radicals Rtogether may be a divalent bridging group having 1 to 10 atoms between the flanking bonds.'}], 'Ris C-C-alkyl, which may be interrupted by one or more O, S, NRor CO and/or may be substituted by one or more identical or different radicals Rselected from CN, COR, COOR, CONRR, phenyl and C-C-cycloalkyl which may interrupted by one or two CO groups and where the two last-mentioned radicals may be substituted by one or ...

POLYMERIZABLE COMPOSITION COMPRISING AN OXIME SULFONATE AS THERMAL CURING AGENT

The present invention relates to a polymerizable composition comprising at least one ethylenically unsaturated, polymerizable compound and at least one oxime sulfonate compound of the formula I 144-. (canceled)47: The compound of formula I according to claim 45 , where{'sup': '14', 'X is S or NRand'}{'sup': 14', '6', '14a', '8', '9', '10', '11', '4', '5', '6', '7', '8', '9', '10', '11, 'sub': 1', '12', '3', '8', '1', '8', '1', '4', '2, 'Ris C-C-alkyl, which may be interrupted by one or more O, S, NRor CO and/or may be substituted by one or more identical or different radicals Rselected from CN, COR, COOR, CONRR, phenyl and C-C-cycloalkyl which may interrupted by one or two CO groups and where the two last-mentioned radicals may be substituted by one or more identical or different radicals selected from C-C-alkyl, C-C-haloalkyl, F, Cl, Br, I, CN, NO, SR, OR, NRR, COR, COORand CONRR;'}{'sub': 2', '12', '3', '8', '1', '8', '1', '4', '2, 'sup': 6', '14a', '8', '9', '10', '11', '4', '5', '6', '7', '8', '9', '10', '11, 'C-C-alkenyl, which may be interrupted by one or more O, S, NRor CO and/or may be substituted by one or more identical or different radicals Rselected from CN, COR, COOR, CONRR, phenyl and C-C-cycloalkyl which may interrupted by one or two CO groups and where the two last-mentioned radicals may be substituted by one or more identical or different radicals selected from C-C-alkyl, C-C-haloalkyl, F, Cl, Br, I, CN, NO, SR, OR, NRR, COR, COORand CONRR;'}{'sub': 3', '12', '1', '8, 'sup': 14b', '8', '9', '10', '11, 'C-C-cycloalkyl, which may be interrupted by one or more CO and/or may be substituted by one or more identical or different radicals Rselected from C-C-alkyl, CN, COR, COOR, CONRR;'}{'sup': 14c', '4', '5', '6', '7', '8', '9', '10', '11, 'sub': 1', '8', '1', '4', '2, 'phenyl, which may be substituted by one or more identical or different radicals Rselected from C-C-alkyl, C-C-haloalkyl, F, Cl, Br, I, CN, NO, SR, OR, NRR, COR, COOR, CONRRand phenyl,'}or ...

SULFIDE ALKYL COMPOUNDS FOR HBV TREATMENT

The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention. 2. (canceled)3. (canceled)4. A composition comprising a compound according to claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , further comprising at least one pharmaceutically acceptable carrier.5. A method of treating an HBV infection in an individual in need thereof claim 1 , comprising administering to the individual a therapeutically effective amount of a compound according to .6. The method of claim 5 , further comprising administering to the individual at least one additional therapeutic agent selected from the group consisting of an HBV vaccine claim 5 , HBV polymerase inhibitor claim 5 , interferon claim 5 , pegylated interferon claim 5 , viral entry inhibitor claim 5 , viral maturation inhibitor claim 5 , BAY 41-4109 claim 5 , reverse transcriptase inhibitor claim 5 , a TLR-agonist claim 5 , AT-61 ((E)-N-(1-chloro-3-oxo-1-phenyl-3-(piperidin-1-yl)prop-1-en-2-yl)benzamide) claim 5 , and AT-130 ((E)-N-(1-bromo-1-(2-methoxyphenyl)-3-oxo-3-(piperidin-1-yl)prop-1-en-2-yl)-4-nitrobenzamide) claim 5 , and a combination thereof.7. The method of claim 6 , wherein the pegylated interferon is pegylated interferon alpha (IFN-α) claim 6 , pegylated interferon lambda (IFN-λ) claim 6 , or pegylated interferon gamma (IFN-γ).8. The method of claim 6 , wherein the reverse transcriptase inhibitor is at least one of Zidovudine claim 6 , Didanosine claim 6 , Zalcitabine claim 6 , ddA claim 6 , Stavudine claim 6 , Lamivudine claim 6 , Abacavir claim 6 , Emtricitabine claim 6 , Entecavir claim 6 , Apricitabine claim 6 , Atevirapine claim 6 , ribavirin claim 6 , acyclovir claim 6 , famciclovir claim 6 , valacyclovir claim 6 , ganciclovir claim 6 , valganciclovir claim 6 , Tenofovir claim 6 , Adefovir claim 6 , ...

SULFONATES OF FURAN-2,5-DIMETHANOL AND (TETRAHYDROFURAN-2,5-DIYL)DIMETHANOL AND DERIVATIVES THEREOF

A process for preparing furanic mono- and/or di-sulfonate molecules from the reduction products of HMF, in particular, from either 2,5-bis-hydroxymethyltetrahydrofurans (THF-diols) or furan-2,5-dimethanol (FDM) under relatively mild conditions is described. The process involves reacting THF-diols or FDM with at least a sulfonate species, and a reagent of either 1) a nucleophilic base or 2) combination of a non-nucleophilic base and a nucleophile, as two separate reagents. The furanic sulfonates synthesized according to the process and some of the associated compounds that can be derivatized from the sulfonates are also provided. 1. A method of preparing a furanic sulfonate compound comprising: contacting a reduction product of 5-(hydroxymethyl)furfural (HMF) with a sulfonate species and a reagent of either 1) a nucleophilic base or 2) a combination of a non-nucleophilic base and a nucleophile.2. The method according to claim 1 , wherein said reduction product of HMF is either a) furan-2 claim 1 ,5-dimethanol (FDM) or b) 2 claim 1 ,5-bis-(hydroxymethyl)-tetrahydrofuran (bHMTHF).3. (canceled)4. (canceled)5. The method according to claim 1 , wherein said sulfonate species is at least one of: mesylate (methanesulfonate) claim 1 , triflate (trifluoromethanesulfonate) claim 1 , tosylate (p-toluenesulfonate) claim 1 , esylate (ethanesulfonate) claim 1 , and besylate (benzenesulfonate).6. The method according to claim 1 , wherein said nucleophilic base is at least: pyrimidine claim 1 , dimethyl-aminopyridine claim 1 , imidazole claim 1 , pyrrolidine claim 1 , and morpholine.7. The method according to claim 1 , wherein said non-nucleophilic base is at least one of: a hindered amine claim 1 , triethylamine claim 1 , diisopropylethylamine claim 1 , dibutylamine claim 1 , a carbonate salt claim 1 , a bicarbonate salt claim 1 , and an acetate salt.8. A sulfonate compound prepared according to claim 1 , wherein said sulfonate compound is either THF-bismethylene monosulfonate or ...

SULFIDE ALKYL COMPOUNDS FOR HBV TREATMENT

The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention. 19-. (canceled)11. The compound of claim 10 , or a pharmaceutically acceptable salt thereof claim 10 , wherein Ris selected from —H claim 10 , halo claim 10 , —OH claim 10 , —CN claim 10 , —C-alkyl claim 10 , —C-alkoxy claim 10 , and —CF.12. The compound of claim 10 , or a pharmaceutically acceptable salt thereof claim 10 , wherein Ris selected from —C-alkyl claim 10 , —C-heteroalkyl claim 10 , —C-cycloalkyl claim 10 , —C-heterocycloalkyl claim 10 , —(C-alkyl)-(C-cycloalkyl) claim 10 , and —(C-alkyl)-(C-heterocycloalkyl) claim 10 , wherein Rmay be optionally substituted with one or two groups independently selected from (═O) claim 10 , —OH claim 10 , —C-alkyl claim 10 , —C(O)OH claim 10 , and halo.13. The compound of claim 10 , or a pharmaceutically acceptable salt thereof claim 10 , wherein each Ris independently selected from halo and —C-alkyl.14. The compound of claim 10 , or a pharmaceutically acceptable salt thereof claim 10 , wherein Ris independently selected from H and halo.15. The compound of claim 10 , or a pharmaceutically acceptable salt thereof claim 10 , wherein each Ris halo.16. The compound of claim 10 , or a pharmaceutically acceptable salt thereof claim 10 , wherein Ris selected from —H claim 10 , halo claim 10 , —CN claim 10 , —C-alkyl claim 10 , —C-alkoxy claim 10 , and tri-halo-(C-alkyl).17. The compound of claim 10 , or a pharmaceutically acceptable salt thereof claim 10 , wherein Ris selected from —H claim 10 , halo claim 10 , —CN claim 10 , —CH claim 10 , —OCH claim 10 , and —CF.18. The compound of claim 10 , or a pharmaceutically acceptable salt thereof claim 10 , wherein Ris halo.19. The compound of claim 10 , or a pharmaceutically acceptable salt thereof claim 10 , wherein Ris selected from —C- ...

Preparation Method Of Polyolefin Reducing Fouling

본 발명은 파울링이 저감된 폴리올레핀의 제조방법에 관한 것으로, 보다 상세하게는 용액중합, 현탁중합 또는 기상중합에 의한 폴리올레핀의 제조방법에 있어서, 상기 중합은 반응기로 CSTR형 반응기, 루프형 반응기 또는 유동층 반응기를 사용하고, 촉매로 지글러-나타 촉매, 메탈로센 촉매 또는 크롬 촉매를 사용하며, 파울링 방지제로 하기 화학식 1 The present invention relates to a method for producing a polyolefin with reduced fouling, and more particularly, in the method for producing a polyolefin by solution polymerization, suspension polymerization or gas phase polymerization, the polymerization is a CSTR reactor, loop reactor or A fluidized bed reactor is used, and Ziegler-Natta catalyst, metallocene catalyst or chromium catalyst is used as a catalyst. [화학식 1] [Formula 1] (상기 R은 탄소수가 5 내지 30인 알킬기이고, n은 0 내지 5이다)로 표시되는 육원자헤테로고리 솔비탄 모노에스터(sorbitan monoester), 화학식 2 Hexatomeric heterocyclic sorbitan monoester represented by (wherein R is an alkyl group having 5 to 30 carbon atoms, n is 0 to 5), and a chemical formula 2 [화학식 2] [Formula 2] (상기 R은 탄소수가 5 내지 30인 알킬기이고, n은 0 내지 5이다)로 표시되는 오원자헤테로고리 솔비탄 모노에스터(sorbitan monoester) 또는 이들의 혼합물을 사용하는 것을 특징으로 하는 파울링이 저감된 폴리올레핀의 제조방법에 관한 것이다. Fouling is reduced by using an o-atomic heterocyclic sorbitan monoester or a mixture thereof represented by (wherein R is an alkyl group having 5 to 30 carbon atoms and n is 0 to 5). It relates to a method for producing a polyolefin. 본 발명에 따르면, 파울링 방지제로 소정의 솔비탄 모노에스터를 사용하여 그 사용량이 적으면서도 반응기 및 이에 포함된 열교환기에 발생하는 파울링의 저감효과가 현저하고 중합활성이 저하되지 않는, 용액중합, 현탁중합 또는 기상중합에 의한 폴리올레핀의 제조방법을 제공하는 효과가 있다. According to the present invention, by using a predetermined sorbitan monoester as the antifouling agent, while the amount thereof is small, the effect of reducing fouling occurring in the reactor and the heat exchanger included therein is remarkable, and the polymerization activity is not lowered. There is an effect of providing a method for producing a polyolefin by suspension polymerization or gas phase polymerization. 파울링, 폴리올레핀, 현탁중합, 기상중합, 지글러-나타 촉매, 솔비탄 모노에스터, 파울링 방지제, 반응기 Fouling, polyolefin, suspension polymerization, gas phase polymerization, Ziegler ...

파울링이 저감된 폴리올레핀의 제조방법

본 발명은 파울링이 저감된 폴리올레핀의 제조방법에 관한 것으로, 보다 상세하게는 용액중합, 현탁중합 또는 기상중합에 의한 폴리올레핀의 제조방법에 있어서, 상기 중합은 반응기로 CSTR형 반응기, 루프형 반응기 또는 유동층 반응기를 사용하고, 촉매로 지글러-나타 촉매, 메탈로센 촉매 또는 크롬 촉매를 사용하며, 파울링 방지제로 하기 화학식 1 [화학식 1] (상기 R은 탄소수가 5 내지 30인 알킬기이고, n은 0 내지 5이다)로 표시되는 육원자헤테로고리 솔비탄 모노에스터(sorbitan monoester), 화학식 2 [화학식 2] (상기 R은 탄소수가 5 내지 30인 알킬기이고, n은 0 내지 5이다)로 표시되는 오원자헤테로고리 솔비탄 모노에스터(sorbitan monoester) 또는 이들의 혼합물을 사용하는 것을 특징으로 하는 파울링이 저감된 폴리올레핀의 제조방법에 관한 것이다. 본 발명에 따르면, 파울링 방지제로 소정의 솔비탄 모노에스터를 사용하여 그 사용량이 적으면서도 반응기 및 이에 포함된 열교환기에 발생하는 파울링의 저감효과가 현저하고 중합활성이 저하되지 않는, 용액중합, 현탁중합 또는 기상중합에 의한 폴리올레핀의 제조방법을 제공하는 효과가 있다. 파울링, 폴리올레핀, 현탁중합, 기상중합, 지글러-나타 촉매, 솔비탄 모노에스터, 파울링 방지제, 반응기

N-hdroxy-2-(alkyl, aryl, or heteroaryl, sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors

Matrix metalloproteinases (MMPs) are a group of enzymes that have been implicated in the pathological destruction of connective tissue and basement membranes. These zinc containing endopeptidases consist of several subsets of enzymes including collagenases, stromelysins and gelatinases. TNF-α converting enzyme (TACE), a pro-inflammatory cytokine, catalyzes the formation of TNF-α from membrane bound TNF-α precursor protein. It is expected that small molecule inhibitors of MMPs and TACE therefore have the potential for treating a variety of disease states. The present invention provides low molecular weight, non-peptide inhibitors of matrix metalloproteinases (MMPs) and TNF-α converting enzyme (TACE) for the treatment of arthritis, tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, diabetes (insulin resistance) and HIV infection having the formula wherein R 2 and R 3 form a heterocyclic ring and A is S, S(O), or S(O) 2 , and R 1 and R 4 are defined herein.

S-substituted [(hetero)aryl]alkylisothioureas, production thereof, pharmaceutical composition, investigation of glutamatergic system, treatment methods (variants)

FIELD: organic chemistry, pharmaceutical industry, medicine. SUBSTANCE: invention relates to new derivatives of S-substituted N-1-[(hetero)aryl]alkyl-N'-1-[(hetero)aryl]alkylisothioureas of general formula I in form of free base and salts with pharmaceutically accepted acids, as well as racemate, individual optical isomers or mixture thereof. In formula R 1 , R 2 , R 3 , R 4 , Y and Z are as described in specification. Compounds of present invention are capable to potentiate (positively modulate) AMPA/KA glutamate receptors and simultaneously to block transmembrane currents induced by activation of NMDA glutamate receptors. Also disclosed are method for production of said compounds, including optical isomers; pharmaceutical composition; method for investigation of glutamatergic system, and method for Alzheimer's disease, treatment; as well as method for extreme retentiveness of memory by administering of effective amount of claimed compounds. EFFECT: new pharmaceutically active compounds for Alzheimer's disease treatment. 23 cl, 1 tbl, 11 ex ÐÎÑÑÈÉÑÊÀß ÔÅÄÅÐÀÖÈß (19) RU (51) ÌÏÊ 7 (11) 2 252 936 (13) C2 C 07 C 335/12, C 07 D 407/12, 409/12, A 61 K 31/155, 31/341, 31/343, 31/36, 31/381, A 61 P 25/28//(C 07 D 407/12, 307:00, ÔÅÄÅÐÀËÜÍÀß ÑËÓÆÁÀ ÏÎ ÈÍÒÅËËÅÊÒÓÀËÜÍÎÉ ÑÎÁÑÒÂÅÍÍÎÑÒÈ, ÏÀÒÅÍÒÀÌ È ÒÎÂÀÐÍÛÌ ÇÍÀÊÀÌ 307:00), (C 07 D 409/12, 317:48, 333:04) (12) ÎÏÈÑÀÍÈÅ ÈÇÎÁÐÅÒÅÍÈß Ê ÏÀÒÅÍÒÓ (21), (22) Çà âêà: 2002132699/04, 05.12.2002 (24) Äàòà íà÷àëà äåéñòâè ïàòåíòà: 05.12.2002 (43) Äàòà ïóáëèêàöèè çà âêè: 20.10.2004 C 2 Àäðåñ äë ïåðåïèñêè: 142432, Ìîñêîâñêà îáë., ×åðíîãîëîâêà, Ñåâåðíûé ïð-ä, 1, ÈÔÀ ÐÀÍ, äèðåêòîðó Í.Ñ.Çåôèðîâó (54) S-ÇÀÌÅÙÅÍÍÛÅ N-1-[(ÃÅÒÅÐÎ)ÀÐÈË]ÀËÊÈË-N`-[(ÃÅÒÅÐÎ)ÀÐÈË] ÀËÊÈËÈÇÎÒÈÎÌÎ×ÅÂÈÍÛ, ÑÏÎÑÎÁ ÈÕ ÏÎËÓ×ÅÍÈß, ÔÀÐÌÀÖÅÂÒÈ×ÅÑÊÀß ÊÎÌÏÎÇÈÖÈß, ÑÏÎÑÎÁ ÈÇÓ×ÅÍÈß ÃËÓÒÀÌÀÒÝÐÃÈ×ÅÑÊÎÉ ÑÈÑÒÅÌÛ, ÑÏÎÑÎÁÛ ËÅ×ÅÍÈß (ÂÀÐÈÀÍÒÛ) R U (57) Ðåôåðàò: Èçîáðåòåíèå îòíîñèòñ ê íîâûì ïðîèçâîäíûì S-çàìåùåííûõ N-1-[(ãåòåðî)àðèë]àëêèë-N'-1[(ãåòåðî)àðèë]àëêèëèçîòèîìî÷åâèíàì îáùåé ...

一种含四氢呋喃、二氟甲硫基类的化合物及其制备方法和应用

本发明涉及一种含四氢呋喃、二氟甲硫基类的化合物，具有如下结构通式（I）。本发明还提供结构通式（I）化合物的制备方法及含有结构通式（I）化合物的液晶组合物。加入了本发明化合物的液晶组合物，响应时间短、Δn数值适中、电荷保持率高，并且具有较低的阈值电压，应用前景广阔。

Process for the preparation of aminomethyl furan derivatives

Aminomethyl furan derivs. (I) are produced from (1) an acylation of (II) and (2) reacting with (III) in the presence of protonic acid i.e. sulfuric acid, methane sulfonic acid or trifluoro methane sulfonic acid. The rxn. performed at 0-5 deg and finally 30-50deg. (I) are useful for the intermediates of histamine H2. The rxn. such as adding acetic acid anhydrous to 5-dimethylamino methyl-2-furan methanol and triethylamine mixt., stirring for 2hr and cooling to give [5-[4-[dimethylamino!methyl -2-furanyl! methyl acetate.

Sulfonium compounds, their preparation and use

式(I)、(Ia)或(Ib)化合物适合作为热产酸剂，其中A 1 - 和A - 例如为(II)，n为1或2；X为C 1 -C 4 亚烷基或CO；Y例如为O、O(CO)、O(CO)O，R 1 例如为氢、C 1 -C 18 烷基、C 3 -C 30 环烷基、苯基、萘基、蒽基、菲基、联苯基、芴基或C 3 -C 20 杂芳基，它们全部任选被取代；R 2 和R 3 例如为任选被取代的C 1 -C 10 卤代亚烷基，或者R 2 和R 3 为任选被取代的亚苯基；R 4 为基团(A)或基团(B)；R 5 和R 6 例如为C 1 -C 20 烷基；或者R 4 和R 5 或R 4 和R 6 一起形成直链C 2 -C 6 亚烷基，R 5 和R 6 一起形成直链C 2 -C 6 亚烷基；R 7 、R 8 、R 9 和R 10 例如为C 1 -C 20 烷基；M例如为C 1 -C 20 亚烷基、C 2 -C 20 亚链烯基、C 2 -C 20 亚炔基；R 25 和R 26 例如为氢、C 1 -C 20 烷基；R 27 、R 28 、R 29 、R 30 和R 31 例如为氢、C 1 -C 20 烷基、C 2 -C 20 链烯基、C 3 -C 20 环烷基，或者两个基团R 27 和R 28 、R 28 和R 29 、R 29 和R 30 和/或R 30 和R 31 一起形成直链C 2 -C 6 亚烷基，或者R 25 和R 27 一起形成1,2-亚苯基，R 33 和R 34 例如为氢、C 1 -C 20 烷基；R 35 、R 36 和R 37 例如为氢、C 1 -C 20 烷基。

Immunosuppressant compounds and compositions

본 발명은 면역억제제, 그들의 제조방법, 그들의 용도 및 그들을 함유하는 약제학적 조성물에 관한 것이다. 본 발명은 림프구 상호작용에 의해 매개되는 질환이나 장애, 특히 EDG 수용체 매개된 신호전달과 관련된 질환의 치료 또는 예방에 유용한 신규 클래스의 화합물을 제공한다. The present invention relates to immunosuppressive agents, their methods of preparation, their use and pharmaceutical compositions containing them. The present invention provides a new class of compounds useful for the treatment or prevention of diseases or disorders mediated by lymphocyte interactions, particularly those associated with EDG receptor mediated signaling. 면역억제제, EDT 수용체. Immunosuppressants, EDT receptors.

IMMUNO DEPRESSANT COMPOUNDS AND COMPOSITIONS

1. Соединение, выбранное из формулы Ia и Ib: ! ! в которых: ! А выбирают из -C(O)OR5, -OP(O)(OR5)2, -P(O)(OR5)2, -S(O)2OR5, -P(O)(R5)OR5 и 1H-тетразол-5-ила; где каждый R5 независимо выбирают из водорода и C1-6алкила; ! W выбирают из связи, C1-3алкилен, C2-3алкенилен; ! Y выбирают из C6-10арила и C2-9гетероарила; где любой арил или гетероарил Y может быть необязательно замещен от 1 до 3 радикалами, выбранными из галогруппы, гидроксигруппы, нитрогруппы, C1-6алкила, C1-6алкоксигруппы, галозамещенного C1-6алкила и галозамещенной C1-6алкоксигруппы; ! Z выбирают из: ! ; ; ; ; ! ; ; ; ; ; ! ; ; ; ; ; ! ; ; ; ; ! ; ; ; ; ! и ! где левая и правая звездочки Z указывают точку присоединения между -С(R3)(R4)- и А формулы Ia или Ib; R6 выбирают из водорода и C1-6алкила; и J1 и J2 независимо обозначают метилен или гетероатом, выбранный из S, О и NR5; где R5 выбирают из водорода и C1-6алкила; и любой алкилен Z может быть далее замещен от 1 до 3 радикалами, выбранными из галогруппы, гидроксигруппы, C1-6алкила; или R6 может быть присоединен к атому углерода в Y с образованием 5-7-членного кольца; ! R1 выбирают из C6-10арил и C2-9гетероарила; где любой арил или гетероарил R1 необязательно замещен радикалом, выбранным из C6-10арилC0-4алкила, C2-9гетероарилC0-4алкила, C3-8циклоалкилC0-4алкила, C3-8гетероциклоалкилC0-4алкила или C1-6алкила; где любая арильная, гетероарильная, циклоалкильная или гетероциклоалкильная группа R1 может быть необязательно замещена от 1 до 5 радикалами, выбранными из галогруппы, C1-6алкила, C1-6алкоксигруппы, галозамещенноу C1-6алкильной группы и галозамещенной C1-6алкоксигруппы; и любая алкильнаях группа из R1 может необязательно иметь метиленовую группу, замещенную атомом или группой, выбранных из -S-, -S(O)-, -S(O)2-, -NR5- и -O-; где R5 выбирают из во РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) 2009 132 108 (51) МПК C07C C07C C07D C07D C07D C07D ФЕДЕРАЛЬНАЯ СЛУЖБА C07D ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ, C07D ПАТЕНТАМ И ТОВАРНЫМ ЗНАКАМ A61K A61K (12) ЗАЯВКА 251/50 ...

Polymerizable composition comprising an oxime sulfonate as thermal curing agent

The present invention relates to a polymerizable composition comprising at least one ethylenically unsaturated, polymerizable compound and at least one oxime sulfonate compound of the formula (I) QA a B b C c where a is 0, 1, 2, 3, 4 or 6, b is 0, 1, 2, 3, 4 or 6, and c is 0, 1, 2, 3, 4 or 6, where the sum of a + b + c is 1, 2, 3, 4 or 6 where (A) is a group (B) is a group (C) is a group where # denotes the point of attachment to Q; X is S or NR 14 and Q, R 1 , R 2 , R 3 and R 14 are as defined in claim 1 and in the description. The present invention also relates to the use of the this composition, to novel oxime sulfonates and the use of the oxime sulfonates as thermal curing promoter.

Polymerizable composition comprising an oxime sulfonate as thermal curing agent

The present invention relates to a polymerizable composition comprising at least one ethylenically unsaturated, polymerizable compound and at least one oxime sulfonate compound of the formula I QA a B b C c   (I) where a is 0, 1, 2, 3, 4 or 6, b is 0, 1, 2, 3, 4 or 6, and c is 0, 1, 2, 3, 4 or 6, where the sum of a+b+c is 1, 2, 3, 4 or 6 where A is a group B is a group C is a group where # denotes the point of attachment to Q; X is S or NR 14 and Q, R 1 , R 2 , R 3 and R 14 are as defined in claim 1 and in the description. The present invention also relates to the use of the this composition, to novel oxime sulfonates and the use of the oxime sulfonates as thermal curing promoter.

Polymerizable composition comprising an oxime sulfonate as thermal curing agent

The present invention relates to a polymerizable composition comprising at least one ethylenically unsaturated, polymerizable compound and at least one oxime sulfonate compound of the formula (I) QA a B b C c where a is 0, 1, 2, 3, 4 or 6, b is 0, 1, 2, 3, 4 or 6, and c is 0, 1, 2, 3, 4 or 6, where the sum of a+b+c is 1, 2, 3, 4 or 6 where (A) is a group (B) is a group (C) is a group where # denotes the point of attachment to Q; X is S or NR 14 and Q, R 1 , R 2 , R 3 and R 14 are as defined in claim 1 and in the description. The present invention also relates to the use of the this composition, to novel oxime sulfonates and the use of the oxime sulfonates as thermal curing promoter.

Process for producing 2,5-diaryltetrahydrofurans and analogs thereof useful as PAF antagonists

Production of ethylene glycol

(57)【要約】 （修正有） 【解決手段】一般式（Ｉ） （式中、Ｒは直鎖又は分枝状のアルキル基；直鎖又は分 枝状のアルケニル基；低級ハロアルキル基などであり、 Ｘ 1 、Ｘ 2 、Ｘ 3 、Ｘ 4 は同一又は異なっていてもよく、水 素原子；ハロゲン原子；低級アルキル基；低級ハロアル キル基；低級アルコキシ基；シアノ基；ニトロ基；アシ ル基又はアリール基であり、Ｙは−ＣＯ−又は−ＳＯ 2 −であり、Ｚは水素原子又はメルカプト保護基である） で表わされる化合物、そのプロドラッグ化合物、その医 薬上許容し得る塩、又はその水和物若しくは溶媒和物を 有効成分としてなるＣＥＴＰ活性阻害剤。 【効果】上記の化合物は、ＣＥＴＰの活性を選択的に阻 害することにより、ＨＤＬを増加させると同時にＬＤＬ を低下させることのできる新しいタイプの動脈硬化若し くは高脂血症の予防又は治療薬として有用性が期待され る。

Patent JPS639515B2

OXYGEN OR SULFUR HETEROCYCLIC COMPOUNDS OF 5 TO 7 CHAIN AND SUBSTITUTED IN POSITION 2, NEMATICIDE AND INSECTICIDE COMPOSITIONS CONTAINING THEM AND PROCESS FOR THEIR PREPARATION

Process for manufacturing substituted aluminum hydrides

Patent FR2195453A1

Patent FR2158018A1

Fluoromethylalkanols and dehydration - products as monomers for products of water

The cpds. are of formula: R+CH2CH=CH-C(CF2X)(CF2X')OH or CH2=CH-CH=C(CF2X)(CF2X') (where R is H opt. substd. alkyl, or aryl, X and X' are Cl or F; and the tetrahydrofuran deriv. from dehydration losing an H on C+ (where R not equal sign H). The polymerisable dehydration products are used for imparting water/grease resistance to paper or fibres.

Preparation of fluorinated organic materials

1430583 Fluorinated organic compounds R N HASZELDINE and R ROWLAND 5 April 1973 [24 Jan 1972] 3328/72 Heading C2C [Also in Divisions C3 and D1] Hexafluoropropene is inserted into a bond between hydrogen and aliphatic carbon in an organic material that is free of acetylenic or terminal olefinic unsaturation, by contacting the hexafluoropropene with the organic compound while exposed to ultra-violet light, in the absence of free oxygen containing gases and free-radical producing catalysts. The organic compound may be a hydrocarbon, or may contain one or more groups or substituents stable under the conditions of the reaction selected from amide, carboxyl, ester, hydroxy, cyanide, ether, thioether, aldehyde, ketones and halogen. It may be a maoromolecule (see Division C3). A solvent may be present. Only one C 3 F 6 unit is inserted into the single C-H bond, but, although single insertion predominates, more than one unit may be inserted into a molecule depending on the nature of the molecule, reactant ratios and conditions. As the net result of the insertion, H is replaced by -CF 2 CFHCF 3 or -CF(CF 3 )(CF 2 H). Many of the products are liquids with low freezing point and good chemical and thermal stability and make useful dielectric liquids, non-corrosive heat exchange materials, solvents and lubricants; products obtained from carboxylic acid have surface active properties; products from alkanes may be dehydrofluorinated to give fluorinated olefins or dienes; products from alkanols may be reacted with acrylic acid to give polymerizable fluoroalkyl acrylates. Insertion into an already fluorinated reactant gives products that are potential aerosol propellants, refrigerants, anaesthetics and intermediates for the preparation of fluoropolymers.

Sulfide alkyl and pyridyl reverse sulfonamide compounds for hbv treatment

The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.

Immunosuppressive compounds and compositions

Η παρούσα εφεύρεση αναφέρεται σε ανοσοκατασταλτικές ουσίες, τη διαδικασία για την παραγωγή τους, τις χρήσεις τους και τις φαρμακευτικές συνθέσεις που περιέχουν αυτές. Η εφεύρεση παρέχει μια νέα κατηγορία ενώσεων χρήσιμων στη θεραπεία ή την πρόληψη ασθενειών ή διαταραχών που προκαλούνται από αλληλεπιδράσεις λεμφοκυττάρων, κυρίως ασθενειών που σχετίζονται με μεταγωγή σήματος που προκαλείται από τον υποδοχέα EDG. The present invention relates to immunosuppressive substances, the process for their production, their uses and the pharmaceutical compositions containing them. The invention provides a new class of compounds useful in the treatment or prevention of diseases or disorders caused by lymphocyte interactions, particularly diseases related to signal transduction induced by the EDG receptor.

Pesticidal 2,4 dinitrophenyl sulphonates

Pesticidal 2,4-dinitrophenyl sulphonates.. M5-. Of formula: (where Y is alkyl (C3-C10) opt. substd. by halo, cycloalkyl (C3-C10), alkenyl (C3-C10), cycloalkenyl (C3-C10), or heterocyclic goup (5 or 6 membered); when X is alkyl (C1-C10), cycloalkyl (C3-C6) opt. substd. by alkyl (C1-C5), alkoxy (C1-C10); or Y = vinyl and X = sec. butyl). Especially, when Y = vinyl, X = sec. butyl; and Y = alkenyl (C3), X = alkyl or cycloalkyl (C3-C10). Used as acaricides, fungicides and herbicides esp. as acaricides on fruits, tomato and cucumber, potato, beet, cereals, cotton, tobacco, coffee, tea and flowers, for control of mildew on potato and cucumber and for control of dicotyledons in cereal crops. May be mixed with compatible pesticides etc.; some mixtures showing synergism. Prepared by.

Tetrahydrofuran compounds and analogs thereof

There are disclosed tetrahydrofuran compounds and analogs thereof of the formula: and pharmaceutically acceptable acid addition salts thereof, wherein X is oxygen or sulfur, R 1 and R 2 are each hydrogen, halogen, lower alkyl or lower alkoxy, and Am is a group of the formula: wherein Z is oxygen or sulfur, R 3 is hydrogen or halogen, R 4 is hydrogen, lower alkyl or phenyl which may be substituted by 1 to 3 substituents at any position(s) on the phenyl nucleus, each substituent being independently selected from halogen, lower alkyl and lower alkoxy, and R 5 is hydrogen or lower alkyl. Such compounds are useful as neuroleptics.

Sulfonium compounds, their preparation and use

Compounds of the formula (I), Ia or (Ib) wherein A 1- and A - is for example (II) is 1 or 2; X is C 1 -C 4 alkylene or CO; Y is for example O, O(CO), O(CO)O, R 1 is for example hydrogen, d-dsalkyl, C 3 -C 30 cycloalkyl, phenyl, naphthyl, anthracyl, phenanthryl, biphenylyl, fluorenyl or C 3 -C 20 heteroaryl, all of which optionally are substituted; R 2 and R 3 for example are C 1 -C 10 haloalkylene which is optionally substituted, or R 2 and R 3 are phenylene, which optionally is substituted; R 4 is a group (A) or a group (B); R 5 and R 6 for example are C 1 -C 20 alkyl; or R 4 and R 5 or R 4 and R 6 together form a straight-chain C 2 -C 6 alkylene, R 5 and R 6 together form a straight-chain C 2 -C 6 alkylene; R 7 , R 8 , R 9 and R 10 ifor example are C 1 -C 20 alkyl; M for example is C 1 -C 20 alkylene, C 2 -C 20 alkenylene, C 2 -C 20 alkynylene; R 25 and R 26 are for example hydrogen, C 1 -C 20 alkyl; R 27 , R 28 , R 29 , R 30 and R 31 are for example hydrogen, C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 3 -C 20 cycloalkyl, or two radicals R 27 and R 28 , R 28 and R 29 , R 29 and R 30 and/or R 30 and R 31 together form a straight-chain C 2 -C 6 alkylene, or R 25 and R 27 together form 1,2-phenylene, R 33 and R 34 for example are hydrogen, C 1 -C 20 alkyl; R 35 , R 36 and R 37 for example are hydrogen, C 1 -C 20 alkyl; are suitable as thermo-acid generators.

Salt compositions from cysteine derivatives or homologues and cysteamine derivatives or homologues

PRECIS DE LA DIVULGATION: Composition pour lutter contre l'aspect gras et inesthétique de la chevelure et pour améliorer l'apparence de la peau, caractérisée par le fait qu'elle contient en tant que composé actif, dans un véhicule approprié, au moins un sel correspondant à la formule suivante: Ia Ib Produits de cette formule et procédé de préparation. PRECISION OF DISCLOSURE: Composition for combating the fatty appearance and unsightly hair and to improve the appearance of the skin, characterized by the fact that it contains as active compound, in a suitable vehicle, at least one salt corresponding to the following formula: Ia Ib Products of this formula and preparation process.

Patent FR2133991B1

Process of making 2,5-diaryl tetrahydrofurans and analogs thereof useful as PAF antagonists

The present invention is directed to a process of making tetrahydrofuran of the formula (D) ##STR1## resulting in 2,5-diaryltetrahydrofuran PAF antagonists of pharmaceutically acceptable purity.

Carbamoyloxy derivatives of mutiline and their use as antibacterials

Derivatives of mutiline of formula (1A) and pharmaceutically acceptable salts and derivatives thereof, in which R1 is ethyl or vinyl, Y is a carbamoyloxy group, in which the N-atom is unsubstituted, or mono- or di-substituted, are useful in the treatment of bacterial infections.

Cetp activity inhibitor

Synthesis and antimicrobial activity of novel dicationic "reversed amidines"

The present invention relates to novel 2,5-bis{[alkyl (or aryl) imino] aminophenyl} furans and thiophenes of the general formula (I) in which R1, R 2, R3 and R4 are each independently selected from the group consisting of H, alkyl, alkoxy, halide, and alkylhalide groups; R5 is H, alkyl or aryl; R6 is H, alkyl, aryl, or NR7R8, in which R7 and R8 are each independently selected from the group consisting of H, alkyl and aryl; and X is O, S or NR9, in whi ch R9 is H or alkyl, and to the use of such compounds.

Azolyl derivatives as fungicides.

Compounds useful as plant growth regulators and fungicides and having the formula < IMAGE > formula (I) and stereoisomers thereof, wherein W is -CH= or =N- Q is optionally substituted aryl, especially optionally substituted phenyl, or optionally substituted aralkyl or alkyl R1, R2, R3, R4, R5 and R6, which may be the same or different, are H, optionally substituted alkyl, cycloalkyl, aralkyl or phenyl R7 and R8 are H, alkyl or optionally substituted phenyl and acid addition salts and metal complexes thereof, and processes and intermediates for their preparation.

Carbamoyloxy derivatives of methiline and their use as antimicrobial agents

본 발명은 하기 화학식 (1A)의 화합물 또는 약제학적으로 허용되는 염, 및 이들의 유도체의 머틸린의 유도체에 관한 것이며, 이들은 박테리아 감염 치료에 유용하다. (화학식 1A) 상기 식에서, R은 에틸 또는 비닐이며, Y는 N-원자가 비치환되거나, 일치환 또는 이치환된 카르바모일옥시기이다.

Nematocides and insecticides and a method of active matter production

Piperazine derivatives useful for the treatment of gastrointestinal disorders

The invention provides compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein R a , R b , R c , R d , R e , R f and Y are as defined in the specification. The compounds are partial or full agonists at the growth hormone secretagogue (GHS) receptors. Pharmaceutical compositions comprising the compounds methods of preparing the compounds, uses of the compounds and methods involving the compounds are also provided.

Sulfide alkyl compounds for HBV treatment

The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.

Patent FI48741B

N-hydroxy-2-(Alkyl,Aryl or Heteroaryl sulfanyl, sulfinyl or sulfonyl) 3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors

Matrix metalloproteinases (MMps) are a group of enzymes that have been implicated in the pathological destruction of connective tissue and basement membranes. These zinc containing endopeptidases consist of several subsets of enzymes including collagenases, stromelysins and gelatinases. TNF-α converting enzyme (TACE), a pro-inflammatory cytokine, catalyzes the formation of TNF-α from membrane bound TNF-α precursor protein. It is expected that small molecule inhibitors of MMPs and TACE therefore have the potential for treating a variety of disease states. The present invention provides low molecular weight, non-peptide inhibitors of matrix metalloproteinases (MMPs) and TNF-α converting enzyme (TACE) for the treatment of arthritis, tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, diabetes (insulin resistance) and HIV infection. The compounds of this invention are represented by the formula where R 1 , R 2 , R 3 and R 4 are described herein.

Patent JPS49124055A

CdS morphology and S vacancy regulation C-H activation building inert chemical bond

本发明公开了一种基于CdS形貌与S空位调节C‑H活化构筑C‑C/C‑N/C‑S键的多相光催化方法，通过制备具有S空位的六方相CdS纳米棒（Sv‑CdS NRs）作为光催化剂，并将催化剂用于C‑H活化构筑C‑C/C‑N/C‑S键以制备2‑乙烯基杂环衍生物等药物中间体或其他精细化学品。Sv‑CdS NRs在无碱性添加剂和氧化剂的存在下，对THF的C‑H活化转化为2‑乙烯基杂环衍生物并附带产氢的反应过程中具有优秀的活性与选择性。Sv‑CdS NRs优秀的光催化性能归因于S空位带来的更多活性位点以及六方晶相所诱导的晶格畸变产生的极化偶极矩和内化电场，这有效地促进了光生电子和空穴的分离。同时，Sv‑CdS NRs在其他的C‑H活化构筑C‑C/C‑N/C‑S键反应类型中均有不错的表现。该催化剂制备方法简单易操作，可用于高效光催化C‑H活化构筑C‑C/C‑N/C‑S键，反应条件温和，催化剂稳定性好且易回收利用。

Reverse sulfonamide compounds based on sulfide, alkyl and pyridyl for the treatment of HBV

compuesto de Fórmula IIIa: **(Ver fórmula)** o una sal farmacéuticamente aceptable del mismo; en la que cada R1 se selecciona independientemente de H, halo y alquilo de C1-6; R2 se selecciona de halo, OH, CN, -alquilo de C1-6, -alcoxi de C1-6, halo-(alquilo de C1-6), di-halo-(alquilo de C1-6) y tri-halo-(alquilo de C1-6); R3 es halo; y R4 se selecciona de -alquilo de C1-6, -heteroalquilo de C1-6, -cicloalquilo de C3-7, -heterocicloalquilo de C3-7, (alquilo de C1-6)-(cicloalquilo de C3-7), -(cicloalquilo de C3-7)-(alquilo de C1-6), cicloalquilo de C7-8 con puente, - (alquilo de C1-6)-C(O)O-(alquilo de C1-6) y -(alquilo de C1-6)-(heterocicloalquilo de C3-7), cada uno de los cuales puede estar sustituido con 0, 1 o 2 grupos seleccionados independientemente de (=O), -OH, -alquilo de C1-6, - cicloalquilo de C3-7, halo-(alquilo de C1-6), di-halo-(alquilo de C1-6), tri-halo-(alquilo de C1-6), C(O)OH, fenilo y halo; o R4 se selecciona de (cicloalquilo de C3-7)-C(O)R5 y -(cicloalquilo de C7-8 con puente)-C(O)R5, y R5 se selecciona de N(CH3)2, NS(O)2CH3, y heterocicloalquilo de C3-7, en los que: "alquilo", por sí mismo o como parte de otro sustituyente, significa, a menos que se señale de otro modo, un hidrocarburo que tiene el número de átomos de carbono designado (es decir, C1-6 significa uno a seis átomos de carbono), e incluye grupos sustituyentes de cadena lineal, ramificada, o cíclicos; y "cicloalquilo" se refiere a un radical no aromático monocíclico o policíclico, en el que cada uno de los átomos que forman el anillo (es decir, átomos esqueléticos) es un átomo de carbono, y/o se refiere a grupos "carbociclilo no aromático insaturado" o "carbociclilo insaturado no aromático", opcionalmente en el que el grupo cicloalquilo comprende un anillo aromático condensado.

Halogenated 4-(4'-bisphenylyl)-butanols

Procedure for the preparation of 4- (4-biphenyl) -butanoles of the general formula I ** (See formula) ** in which the radical R1 signifies a halogen atom or the amino group, the radical R2 signifies a hydrogen or halogen atom and the radical R3 signifies a hydrogen atom, and of its salts with organic or inorganic acids, if R1 represents an amino group, characterized in that it is treated with catalytically activated hydrogen in the presence of acidic agents to a tetrahydrofuran derivative of the general formula II ** (See formula) ** wherein the radicals R1 and R2 are as defined above; and if desired, a compound of formula I obtained is then transformed, in which the radical R1, signifies an amino group, by means of organic or inorganic acids, into their acid addition salts. (Machine-translation by Google Translate, not legally binding)

A PROCEDURE FOR THE PREPARATION OF NEW BENZO-MELTED TRICYCLE COMPOUNDS.

PROCESS FOR PREPARATION OF 4- (4-BIPHYLILYL) -BUTANOL COMPOUNDS

Catalyst and catalytic process for the etherification/reduction of furfuryl derivatives to tetrahydrofurfuryl ethers

The invention relates to a method for producing tetrahydrofurfuryl ethers, characterised in that it involves carrying out consecutive etherification/reduction reactions based on a compound containing at least one furan ring, in the presence of at least one alcohol and at least one catalyst, optionally in the presence of H 2 . The catalytic process can be carried out in a cascade reaction ("one-pot"), operating under soft reaction conditions and without a solvent.

N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors

Matrix metalloproteinases (MMPs) are a group of enzymes that have been implicated in the pathological destruction of connective tissue and basement membranes. These zinc containing endopeptidases consist of several subsets of enzymes including collagenases, stromelysins and gelatinases. TNF converting enzyme (TACE), a pro-inflammatory cytokine, catalyzes the formation of TNF-α from membrane bound TNF-α precursor protein. It is expected that small molecule inhibitors of MMPs and TACE therefore have the potential for treating a variety of disease states. The present invention provides low molecular weight, non-peptide inhibitors of matrix metalloproteinases (is) and TNF-α converting enzyme (TACE) for the treatment of arthritis, tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, diabetes (insulin resistance) and HIV infection having the formula wherein R 2 and R 3 form a heterocyclic ring and A is S, S(O), or S(O)2, and R 1 and R 4 are defined herein.

Sulfide alkyl and pyridyl reverse sulfonamide compounds for hbv treatment

The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.

Patent JPS49132090A

Fluorinated monomer of cyclic acetal structure, polymer, resist protective coating composition, resist composition, and patterning process

본 발명은 화학식 (1)로 표시되는 환상 아세탈 구조를 갖는 불소 함유 단량체를 제공한다. The present invention provides a fluorine-containing monomer having a cyclic acetal structure represented by the formula (1). (R은 수소 원자의 일부가 할로겐 원자로 치환될 수도 있으며, 메틸렌기의 일부가 산소 원자 또는 카르보닐기로 치환될 수도 있는 탄소수 1 내지 20의 직쇄상, 분지상 또는 환상 알킬기, Z는 양끝에서 결합하는 알킬렌옥시기와 함께 오원환 또는 육원환을 형성하고, 중합성 불포화기를 포함하는 2가의 유기기) (R is a straight, branched or cyclic alkyl group of 1 to 20 carbon atoms in which some of the hydrogen atoms may be substituted with halogen atoms, some of the methylene groups may be substituted with an oxygen atom or a carbonyl group, Z is an alkyl A divalent organic group which forms a 5-membered ring or a 6-membered ring together with a phenoxy group and a polymerizable unsaturated group) 본 발명에 의해 광기능성 재료, 코팅 재료 등의 원료로서 유용한 환상 아세탈 구조를 갖는 신규 불소 함유 단량체가 제공된다. 그 중에서도, 상기 단량체를 이용한 중합체는 파장 200 nm 이하의 방사선에 대하여 우수한 투명성을 갖고, 또한 우수한 발수성을 가짐과 동시에 구조의 선택에 따라 발수성, 지용성, 산분해성, 가수분해성 등 각종 성능의 조정이 가능하다. The present invention provides a novel fluorine-containing monomer having a cyclic acetal structure useful as a raw material for a photo-functional material, a coating material and the like. Among them, polymers using the above monomers have excellent transparency to radiation having a wavelength of 200 nm or less, have excellent water repellency, and can adjust various performances such as water repellency, oil solubility, acid decomposability and hydrolysis ability depending on the structure Do. 불소 함유 단량체, 고분자 화합물, 레지스트 보호막 재료, 레지스트 재료 Fluorine-containing monomer, polymer compound, resist protective film material, resist material

Patent CS166825B2

Method of producing derivatives of hexahydropyrrole (1.2-a)quinoline or hexahydropyrido (1.2-a)quinoline,or octahydrophenanthrene

Изобретение касаетс  конденсированных гетероциклических систем, в частности производных гексагидропир- роло(1,2-а)хинолина. или гексагидро- пиридо(1,2-а)хинолина, или октагидро- фенантрена общей формулы: НО-СН2-СН2, он р I -0-С-ССНг )зХ2) , RI (IJ где R и RX - один метил, а другой водо- род,М --N или СН,причем когда М - N,Tq или 2j когда М - СН, то ,которые обладают анальгетической активностью и могут быть использованы в медицине. Цель - создание активных веществ ука- i занного класса.Получение указанных веществ ведут восстановлением соединений общей формулы (II) или (III) НО-С(0)-СН,ОИ К W -о-9-(снгЪ-{§ Н (U) RI (III); о-счсн2 )з-Хо) . 2 где R, R/ и п указаны вьше, с помощью алюмогидрида лити  в тетрагидро- фуране или лити  в безводном жидком аммиаке. Активность веществ выше кофеина и морфина. 1 табл. СО с САЗ СП ел 00 04 The invention relates to condensed heterocyclic systems, in particular hexahydropyrrolo (1,2-a) quinoline derivatives. or hexahydro-pyrido (1,2-a) quinoline, or octahydrophenanthrene of the general formula: HO-CH2-CH2, it p I -0-C-CCNg) xX2), RI (IJ where R and RX are one methyl, and other hydrogen, M is N or CH, and when M is N, Tq or 2j when M is CH, then those that have analgesic activity and can be used in medicine. The goal is to create active substances of the above class .The preparation of these substances is carried out by the reduction of compounds of the general formula (II) or (III) HO-C (0) -CH, OI K W -o-9- (cnb- {§ H (U) RI (III); o-func2 ) s-ho). 2 where R, R / and p are indicated above, using lithium aluminum hydride in tetrahydrofuran or lithium in anhydrous liquid ammonia. The activity of substances above caffeine and morphine. 1 tab. SO with SAZ JV ate 00 04

Azolylmethyltetrahydrofurans

Nematicide and insecticide compositions containing heterocyclic compounds

The compositions contain as active material a compound of formula: <IMAGE> with: n = 1, 2 or 3; X = O, S; Rx = H, optionally halogenated C1-C6 alkyl; R1 and R2: identical or different: H, halogen, (halogenated) C1-C3 alkyl; Y = H, XR, halogen, ammonium, sulphonium, phosphonium, with R = (halogenated) alkyl, C(X)R', SO2R', -N=C(R3R4), with R' = C1-C6 alkyl, optionally substituted phenyl; XR3, NR3R4 with R3 and R4 identical or different: H, C1-C4 alkyl. Application to plant protection.

Fluoromethylated alkenols and their dehydration products and processes for the preparation of these compounds and their use

Piperazine derivatives useful for the treatment of gastrointestinal disorders

The invention provides compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Ra, Rb, Rc, Rd, Re, Rf and Y are as defined in the specification. The compounds are partial or full agonists at the growth hormone secretagogue (GHS) receptors . Pharmaceutical compositions comprising the compounds, methods of preparing the compounds, uses of the compounds and methods involving the compounds are also provided.

Furan based compositions and methods of making thereof

wherein a and c are independently 0 or 1, b and d are independently 1 or 2, x and y are independently 1 or 2, dependent upon the values of a-d, m and o are independently 0 or 1, n is an integer of 0-6, and each A is independently an unsaturated furan ring, a partially saturated furan ring, a saturated furan ring, or —(CH2)4—. Also, R1, R1′, R2, R3, R4 and R5 are independently selected from the group consisting of H and alkyl groups having 1 to 18 carbon atoms, with a proviso that at least one of R2, R3, R4, and R5 is not hydrogen, and the total carbon content of the compound of formula (I) is in the range of 20-62.

Reversed amidines and methods of using for treating, preventing, or inhibiting leishmaniasis

Methods for treating, preventing or inhibiting leishmaniasis in a subject comprising administering to the subject a therapeutically effective amount of at least one compound having the structural formula wherein Y is a heteroatom; R 1 and R 2 are independently H or an alkyl, cycloalkyl, heterocycloalkyl, aryl, amino or heteroaryl group; and X 1 , X 2 , and X 3 are independently H or an alkyl, alkoxy, halo, amino, alkylamino, dialkylamino, acylamino, alkylthio, sulfonyl, cyano, carboxy, alkoxycarbonyl, or carbamoyl group are disclosed.

Novel process of producing phenyl or substituted phenylalkylamine pharmaceutical agents and novel chiral intermediates of high enantiomeric purity useful therein

A process for producing the optically pure (+)- or (-) isomer of a phenyl- or substituted- phenylalkanolamine compounds having pharmacologic activity without the need for resoltuion processes ad novel intermediates useful in the process including optically pure haloalcohols are provided.

COMPOSITION FOR HAIR COSMETICS

Sulfonium compounds

ABSTRACT: Sulfonium compounds represented by the formula

Sulfonium sulfate and its manufacture and use

Patent FR2133992A1

Compound having a five-membered ring, the liquid crystal composition and the liquid crystal display device

The invention provides a liquid crystal compound that has an excellent compatibility with other liquid crystal compounds and also has at least one of characteristics such as a high stability to heat, light or the like, a suitable refractive index anisotropy (Δn), a low threshold voltage and a suitable dielectric anisotropy (Δ∈). A compound represented by formula (1) For example, R 1 is alkyl having 1 to 10 carbons, R 2 is halogen or alkenyl having 2 to 10 carbons; the ring A 1 , the ring A 2 and the ring A 3 are 1,4-cyclohexylene or 1,4-phenylene; Z 1 , Z 2 and Z 3 are a single bond or alkylene having 1 to 4 carbons; G is —CH 2 — or —O—; and m is 1, and n and p is 0 or 1.

CHIRAL IMIDODIPHOSPHATE, ITS PREPARATION AND USE PROCESS

imidodifosfatos quirais e derivados destes a presente invenção refere-se a imidodifosfatos quirais e derivados destes tendo a fórmula geral i, (i) os compostos são adequados como catalisadores de ácido de brønsted quiral, catalisadores de transferência de fase, ânions quirais para sais orgânicos, sais metálicos ou complexos metálicos para catálise. chiral imidodiphosphates and derivatives thereof the present invention relates to chiral imidodiphosphates and derivatives thereof having the general formula i, (i) the compounds are suitable as chiral brønsted acid catalysts, phase transfer catalysts, chiral anions for organic salts, metallic salts or metal complexes for catalysis.

Unsaturated aromatic amides as pesticides

CEPT ACTIVITY INHIBITORS

Patent FR2195453B1

FUNGICID COMPOUNDS AND COMPOSITES AND PLANT GROWTH REGULATORS, PROCESS FOR THEIR PREPARATION, PROCESS TO REGULATE PLANT GROWTH AND PROCESS TO COMBAT DISEASES CAUSED BY Fungi

COSMETIC TO COMBAT THE OILY AND UNASTHETIC APPEARANCE OF HAIR AND TO IMPROVE THE APPEARANCE OF THE SKIN

Substituted cyclic and heterocyclic methane sulfonates

There are provided compounds which are alkyl sulfonates substituted on a 5-membered heterocyclic or cyclic ring. The hetero-substituents of the ring may be O, S, R 2 N, R 3 R 4 + N<, ##STR1## where R 2 , R 3 and R 4 are the same or different substituted or unsubstituted, and are hydrogen, alkyl or aryl. Optionally, the hetero-substituent may be replaced by R 3 R 4 C. The alkyl sulfonate substituent is in the 3 position of the ring and a substituted or unsubstituted alkyl substituent is in the 4 position of the ring. The compounds may be prepared by reacting X(CH 2 CH═CHR) 2 , where X is the above mentioned hetero-substituents or R 3 R 4 C<, with a bisulfitc salt.

Imidate compound and use thereof for pest control

There is provided a compound having an excellent controlling effect on arthropod pests represented by the formula (I-1): wherein Z represents an optionally substituted carbocyclic group or an optionally substituted heterocyclic group; G represents a -A1-R1 group, etc.; X represents a -A2-R4 group, etc.; X0 represents a -A3-R6 group, etc.; or X and X0 are optionally taken together to form a -A2-T0-A3- group; M1 represents a -R8 group, etc.; A1, A2 and A3 independently represent an oxygen atom, etc.; R1 and R8 independently represents an optionally substituted C1-C20 chain hydrocarbon group, etc.; R4 and R6 independently represent an optionally substituted C1-C6 chain hydrocarbon group, etc.; and T0 represents an optionally substituted C2-C6 alkanediyl group.

COSMETIC TO COMBAT THE OILY AND UNASTHETIC APPEARANCE OF HAIR AND TO IMPROVE THE APPEARANCE OF THE SKIN

Composition for controlling nematode and insect

(57)【要約】本公報は電子出願前の出願データであるた め要約のデータは記録されません。

Fluorinated monomer of cyclic acetal structure, polymer, resist protective coating composition, resist composition, and patterning process

A fluorinated monomer of cyclic acetal structure has formula (1) wherein R is a C 1 -C 20 alkyl group which may be substituted with halogen or separated by oxygen or carbonyl, and Z is a divalent organic group which forms a ring with alkylenoxy and contains a polymerizable unsaturated group. A polymer derived from the fluorinated monomer may be endowed with appropriate water repellency, water sliding property, lipophilicity, acid lability and hydrolyzability and is useful in formulating a protective coating composition and a resist composition.

Novel substituted sulfonylurea derivatives

本发明涉及新的通式(I)杂环化合物其可药用盐、可药用溶剂合物、对映体、非对映体和多晶型物。本发明还涉及用于制备本发明化合物的方法、包含所述化合物的药物组合物以及本发明化合物属于NOD样受体家族(NLR)蛋白NLRP3调节剂家族所带来的用途。因此，本发明涉及新的NLRP3调节剂以及涉及新的抑制剂化合物在治疗其中涉及白介素1β活性的疾病或病症中的用途。

Catalyst and catalytic process for the etherification/reduction of furfuryl derivatives to tetrahydrofurfuryl ethers

New compositions based on derivatives or homologues of cysteamine and processes to counteract the greasy and aesthetically unattractive appearance ofthe head or hair and to improve the appearance ofthe skin, new compounds and process for their preparation

Heterocyclic alkylthiocyanate and isothiocyanate plant growth regulators

4-(4-biphenylyl)-butanols

PROCEDURE FOR THE PREPARATION OF BENZO-CONDENSED TRICYCLIC COMPOUNDS OR PHARMACEUTICAL ACCEPTABLE SALTS THEREOF AND INTERMEDIATES THEREOF

Process for the preparation of substituted hexahydro benzo (e) indene and octahydro phenanthrene

Title compds. (I) [m=0,1,2; t=1,2; M=CH, N; R1=H, benzyl, benzoyl, C1-5 alkanoyl, etc.; Q=CO2R4, COR5, 5-tetrazollyl, etc.; R4=H, C1-4 alkyl, benzyl; R5=H, C1-4 alkyl, Ph, benzyl , useful as an analgesic, were prepd.. Thus, a mixt. contg. 28.6g 3, 5-dimethoxy-β-nitrostyrene, 20 g butadiene, 40ml toluene, and small amt. of hydroquinone was cooled to -78↿C under nitrogen followed by boiling at 100↿C for 48hr, cooled again, concentrated, and crystallized by MetOH to give 29.8g 4-(3,5-dimethoxyphenyl)-5nitrocyclohexene.